ADCT News and Press, ADC Therapeutics SA

ADC Therapeutics to Participate in March Investor Conferences PR Newswire LAUSANNE, Switzerland , Feb. 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced par...

ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement PR Newswire LAUSANNE, Switzerland , Feb. 23, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announ...

2026-02-13 14:01:58 ET More on pharmaceuticals, biotech Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More BBH: Mature Biotech Exposure, But Limited Growth Ahead XPH: Healthcare Dashboard For January Most and least shorted m...

$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. Equity-Insider.com   News Commentary   VANCOUVER, BC , Jan. 30, 2026 /CNW/ -- The oncology sector is underg...

2026-01-15 16:15:59 ET ADC Therapeutics SA (ADCT) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 1:30 PM EST... Read the full article on Seeking Alpha For further details see: ADC Therapeutics SA (ADCT) Presents at 44th Annual J.P. Morgan Healthcare Conferenc...

2026-01-08 16:25:12 ET More on ADC Therapeutics ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL - Slideshow ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Eva...

ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates PR Newswire Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equ...

ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference PR Newswire LAUSANNE , Switzerland , Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADC...

ADC Therapeutics Announces New Employee Inducement Grant PR Newswire LAUSANNE , Switzerland , Jan. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the...

Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines Canada NewsWire Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC , Dec. 19, 2025 /CNW/ -- Equity Insider News Commentary – The oncology sector's pivot toward platf...